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• Corticosteroids are widely used for autoimmune/inflammatory disease, but 
responses are variable 
• In vitro, CD4+ T cells from steroid refractory ITP patients express a lower IL-10:IL-17 
ratio 
• We confirm this finding in an independent cohort of patients with autoimmune 
disease  





Corticosteroids remain the first line treatment for patients with Immune Thrombocytopenia 
(ITP). However, 20-30% of patients do not respond to treatment at tolerable doses. This 
variation in corticosteroid efficacy is replicated in other autoimmune diseases and may have 
an adaptive immune basis. 
Objective 
To test the hypothesis that CD4+ T cell responses to corticosteroids are different in patients 
with clinically defined corticosteroid refractory ITP. 
Methods 
In this prospective cohort study, CD4+ T cells from patients with ITP were cultured in the 
presence or absence of dexamethasone (Dex). Intracellular cytokine expression was then 
quantified by flow cytometry and compared with patients’ clinical response to 
corticosteroid treatment. A control cohort of patients with autoimmune uveitis was also 
studied to evaluate whether our findings were limited to ITP or are potentially generalizable 
across autoimmune diseases.    
Results 
The ratio of interleukin (IL)-10 to IL-17 expression following CD4+ T cell culture with Dex was 
able to discriminate between ITP patients with a clinically defined complete (n=33), partial 
(n=12) or non-response (n=11) to corticosteroid treatment (p=0.002). These findings were 
replicated in patients with autoimmune uveitis (complete response n=14, non-response 
n=22; p=0.01)  
Conclusions 
There is a relative abrogation of IL-10 and persistence of IL-17 expression in the CD4+ T cells 
of patients who clinically fail corticosteroid therapy. This observation has potential to inform 
both our mechanistic understanding of the action of corticosteroids in the treatment of ITP, 
and as a biomarker for steroid refractory disease, with potential application across a range 











Corticosteroids are one of the most widely prescribed drugs in medicine. However, the 
doses needed to achieve disease remission varies enormously across inflammatory and 
autoimmune conditions and between individuals with a significant proportion of patients 
failing to respond at tolerable doses. Corticosteroids are also associated with a plethora of 
metabolic, endocrine, gastrointestinal, psychological and musculoskeletal side-effects [1]. In 
haematology, corticosteroids are standard treatment for many conditions including immune 
thrombocytopenia (ITP), autoimmune haemolytic anaemia, acquired haemophilia, 
thrombotic thrombocytopenic purpura, myeloma and lymphoid cancers. ITP is an 
autoimmune illness with a risk of bleeding due to thrombocytopenia that results from 
increased consumption and decreased production of platelets [2]. Recent guidelines 
continue to recommend high dose corticosteroids as first line treatment for ITP but 
responses are heterogeneous with 20-30% of patients refractory to treatment and the 
burden of corticosteroid side-effects remains a major clinical challenge [3]. 
The main actions of corticosteroids on the immune system are mediated by activation of the 
glucocorticoid receptor (GR). As such, in vitro studies are typically conducted with a pure 
glucocorticoid such as dexamethasone. The GR has near ubiquitous expression in the body, 
and binding of glucocorticoids to the GR results in a variety of cellular responses, including 
the transactivation of anti-inflammatory genes and transrepression of pro-inflammatory 
genes [4]. However, the biological basis underlying the variable response to corticosteroids 
is not well understood. Several molecular mechanisms have been proposed, including 
defective GR binding and nuclear translocation, increased expression of the inhibitory 
isoform GRβ, and polymorphisms in accessory proteins [5]. However, no strong associations 
with known GR polymorphisms have been found in ITP [6].  
More broadly, there is increasing evidence to suggest that the intrinsic sensitivity of an 
individual’s lymphocytes may be a major factor in determining their response to 
corticosteroids [7]. Early studies of adaptive immunity in corticosteroid responsiveness 
focused on CD4+ T helper (Th) cells, and more recently the importance of cytokine 
expression within these populations has been revealed. In particular, Hawrylowicz et al have 
demonstrated a failure to upregulate interleukin (IL)-10 in corticosteroid resistant asthma 
patients [8, 9] while others have shown a bias towards pro-inflammatory IL-17 expression 
over interferon (IFN)-γ [10, 11]. This has been corroborated in a range of autoimmune 
conditions [12-14]. Furthermore, a number of cytokine gene polymorphisms have been 
associated with the effectiveness of corticosteroid therapy in ITP, including specific IL-10 
and IFN-γ genotypes [15, 16]. These data infer an adaptive immune basis to diversity of 
clinical corticosteroid responsiveness. 
We therefore hypothesized that the same phenomenon would be observed in ITP and 
sought to develop a functional T cell assay to quantify upregulation of IL-10 after exposure 
to dexamethasone in parallel with IL-17 expression. In this preliminary study, we tested this 
assay in a mixed cohort of ITP patients, and, to evaluate the potential generalizability of this 
work to other autoimmune diseases, in parallel, we evaluated a control cohort of patients 
with autoimmune eye inflammation (uveitis). Our goal was to interrogate the continuum of 
corticosteroid response in patients from an adaptive immune T cell perspective, both to 
shed light on underlying mechanisms of disease and to assess the potential for this to be the 






Patients with a diagnosis of ITP aged 16 years and over were recruited following informed 
written consent in accordance with the Declaration of Helsinki (study registration details: 
https://www.isrctn.com/ISRCTN95606674, NHS Research Ethics Committee ref: 
15/LO/2088). Patients with a complete response (CR) were defined as achieving a platelet 
count of >100x109/L with single agent, first line oral prednisolone treatment (1mg/kg daily)  
within 2 weeks of treatment initiation, whereas non-responsive (NR) patients were defined 
by a platelet count of <30x109/L, or less than a 2-fold increase from baseline after 2 weeks 
of treatment. If patients achieved a platelet count of 30-100x109/L and 2-fold increase from 
baseline they were classified as a partial responder (PR). At time of recruitment, patients 
could be receiving any ITP-directed therapy (Table 1).  
Control cohorts of autoimmune uveitis patients and healthy donors were also recruited 
following informed consent (UK NHS Research Ethic Committee reference: 04/Q2002/84). 
The definition of corticosteroid resistance in autoimmune uveitis was failure to taper to a 
dose of 10mg/day prednisolone as previously described [12].  
Cell isolation and culture 
Peripheral blood was acquired by venepuncture, and CD4+ T cells isolated through negative 
selection using a RosetteSepTM Human CD4+ T cell enrichment cocktail (StemCell 
Technologies, Canada) as per the manufacturer’s protocol. Purified CD4+ T cells were 
resuspended to a concentration of 1 x 106 cells/ml in RPMI 1640 growth medium containing 
10% FCS, L-Glutamine and Penicillin/Streptomycin. Cells were activated with Human T 
Activator CD3/CD28 Dynabeads (ThermoFisher Scientific, UK) and 50IU/ml recombinant 
human IL-2 (Roche, UK), and cultured with or without dexamethasone (Dex; 1 x 10-6M) for 
96 hours (unless otherwise stated) under tissue culture conditions. Unstimulated cells at the 
point of isolation (day 0) were also examined as a pre-culture sample.  
Intracellular staining 
PMA (20ng/ml), ionomycin (1µM) and GolgiStop (2µM; BD Biosciences, USA) were added to 
the cell culture for the last 4 hours. Cells were then stained with a Live/Dead viability dye 
(ThermoFisher Scientific) for 30 minutes before fixation and permeabilization using BD 
Cytofix/Cytoperm Kit (BD Biosciences) for 15 minutes. Intracellular cytokine expression was 
measured using the following antibodies: IL-10-eFluor660 (JES3-9D7; ThermoFisher 
Scientific), IL-17-BrilliantVioletTM 605 (BL168; BioLegend, USA), and IFNγ-PerCP-Cy5.5 (4S.B3; 
ThermoFisher Scientific). Fluorescence was then measured by flow cytometry using a BD 
Fortessa X20 or BD LSR II (BD Biosciences).  
Data analysis 
Analysis was performed using FlowJo software (TreeStar Software, USA) and carried out in a 
masked fashion so that the assessor was blind to the clinical response of the patient. Live 
singlets were gated, and the percentage of cytokine positive cells determined by using 
fluorescence minus one (FMO) controls. The proportion of IL-10+ and IL-17+ cells was used 




software (San Diego, CA). Mann-Whitney U tests were performed between groups, and a P 
value of <0.05 was considered significant. 
 
Results and Discussion 
We initially aimed to characterize the kinetics of CD4+ T cell cytokine expression in the 
presence of dexamethasone in cells isolated from healthy controls. An increase in the 
proportion of IL-10-producing CD4+ T cells compared to T cell activation alone was 
demonstrated, with a significant difference seen from 4 days of culture onwards (Figure 1A). 
This IL-10 expression occurred in a dose-dependent manner (Figure 1B). The day 4 timepoint 
also showed the least differential of IL-17 (Figure 1C), and the greatest suppression of IFN-y 
(Figure 1D), which is consistent with other reports [9]. Consequently, the day 4 timepoint 
was chosen for this assay.  
To determine whether clinical non-responsiveness to corticosteroid treatment in ITP 
patients correlated with the in vitro cytokine response of CD4+ T cells, 56 adults with ITP 
were recruited from University Hospitals Bristol NHS Foundation Trust. In total, 33 CR, 11 
NR, and 12 PR patients were recruited, with a median age of 53 years (range 16-85), and 26 
females (Table 1). Dexamethasone treatment in vitro resulted in a significant increase in the 
proportion of IL-10+ CD4+ T cells compared to T cell activation across all patient groups 
(Figure 2A, B). In contrast, the proportion of IL-17+ CD4+ T cells following dexamethasone 
treatment was only increased in CR patients (Figure 2C). Dexamethasone did not suppress 
IFN-γ expression after 4 days culture regardless of clinical response to corticosteroid 
treatment (Figure 2D). In contrast this was suppressed in healthy donors (Figure 1D) and the 
maintenance of IFN-γ in ITP therefore potentially reflects underlying immune activation in 
the context of disease. Nonetheless, when comparing the change in intracellular expression 
of individual cytokines after culture with dexamethasone in CD4+ T cells from NR, PR and CR 
patients, neither IL-10, IL-17 or IFN-γ expression in isolation was discriminatory. However, 
when the ratio of IL-10 to IL-17 in CD4+ T cells was examined, this was significantly elevated 
in dexamethasone treated CD4+ T cells from CR compared with NR patients (6.02  +/- 2.98 
CR vs 3.22 +/- 1.75 NR, p=0.002; Figure 2E, F). This IL-10:IL-17 ratio was also able to 
distinguish between CR and NR patients with an area under the receiver operating 
characteristic (ROC) curve of 0.81, indicating significant predictive power (95% confidence 
intervals 0.668, 0.952, p=0.002) (Figure 2G). We have interpreted this in vitro observation as 
a glucocorticoid-dependent phenomenon, rather than a reflection of disease severity, as 
there was no significant difference in the expression of IL-10, IL-17 or IFN-γ between CR, PR 
and NR groups directly ex vivo, pre-culture (Figure 3A-D).  
Furthermore, to confirm the generalizability of these findings, we recruited a second cohort 
of 36 corticosteroid-treated patients with autoimmune uveitis. Fourteen of these patients 
had a complete response, and 22 were non-responsive in accordance with previously 
published criteria [12]. The in vitro response to dexamethasone of CD4+ T cells from uveitis 
patients replicated our findings in ITP, with CR patients showing increased IL-10+ (Figure 4A, 
B) and decreased IL-17+ (Figure 4A, C) CD4+ T cells compared to NR patients, resulting in a 




patients (3.19 +/- 2.25 CR vs 1.74 +/- 2.14 NR, p=0.01; Figure 4E, F), and an area under the 
ROC curve of 0.76 (95% confidence intervals 0.599, 0.914, p=0.01; Figure 4G). In addition, 
consistent with ITP, there was no difference in the proportion of IFN-γ+ T cells between CR 
and NR uveitis patients (Figure 4D).  
In common with other immune-driven diseases, these data strongly support the concept of 
an adaptive immune basis for clinical heterogeneity in patients’ response to corticosteroid 
treatment in ITP. We have refined this to CD4+ T helper cell subsets, demonstrating a 
reduced IL-10:IL-17 ratio in NR patients. This reflects a relative abrogation of IL-10 and 
persistent IL-17 expression in patients who fail to respond.  
There is increasing evidence that the dysregulation of CD4+ T cells plays a central role in the 
pathogenesis of ITP. Several studies have identified an imbalanced Th1/Th2 ratio, with 
increased Th1 cells and an associated rise in the production of pro-inflammatory cytokines 
such as IFN-γ and tumour necrosis factor (TNF)-α [17-19]. Additionally, increased numbers 
of pro-inflammatory Th17 cells, and reduced numbers of regulatory T cells (Tregs) have 
been described in patients with ITP [20-22]. The clinical efficacy of glucocorticoids in ITP 
may therefore be in part due to their capacity to rebalance these T helper populations 
through the induction of the anti-inflammatory cytokine IL-10. Indeed, high dose 
dexamethasone treatment has been reported to restore a normal Th1/Th2 ratio, reduce 
Th17 cells, and increase the number of Tregs [23]. A subset of CD45RA-FoxP3hi Tregs with 
high IL-10 expression has also been correlated with greater sensitivity to corticosteroid 
treatment [24]. Corticosteroids can also upregulate IL-10 expression in other cell types, 
including CD8+ T cells [25, 26] and B cells [27]. Indeed, the frequency of IL-10+ B cells 
positively correlates to a high Treg/Th17 ratio and a good treatment outcome in ITP patients 
[28].  
CD4+ T cells that upregulate IL-10 in response to dexamethasone often co-produce Th17-
associated cytokines, including IL-17, IL-22, and IFN-γ [9]. These IL-10-producing Th17 cells 
have been termed “non-pathogenic” Th17 cells, and are important in limiting inflammation 
and autoimmunity [29]. In contrast, a subset of CD4+ T cells that co-express IL-17 and IFN-γ, 
so-called “pathogenic” Th17 cells, have been shown to be unresponsive to corticosteroids. 
These cells do not express IL-10 [11] and their proliferation is not suppressed by 
dexamethasone [10]. Thus, in patients who fail to respond to corticosteroids by 
upregulating IL-10, we hypothesize that there may be a preferential outgrowth of IL-17+IFN-
γ+ pathogenic Th17 cells, contributing to persistent, corticosteroid refractory disease.  
A limitation of this study is the mixed cohort of ITP patients at various stages of disease 
duration and receiving a range of treatments, as well as the low number of NR patients 
recruited. Whilst there are no clear indications that age, gender, or chronicity of disease 
have significantly influenced our findings (Table 1), it would be necessary to prospectively 
validate this finding in a larger cohort of newly diagnosed ITP patients. For a small number 
of patients (n=9, 4 CR, 3 PR and 2 NR), a repeat sample was taken 1 to 13 months after the 
initial sample. The IL-10:IL-17 ratio was not significantly changed between the two time 
points (paired t-test; mean of differences -1.138, S.D. of differences 3.028, p=0.2922), 
despite the fact that all but one of the patients had changed treatment regime at the second 
time point. However, a larger prospective cohort is required to definitively evaluate whether 




There is also some evidence that ITP patients who have anti-GPIb complex antibodies are 
more resistant to corticosteroid therapy [30]; it would therefore be interesting to examine 
the relationship between CD4+ T cell cytokine expression and the presence of anti-GPIb 
antibodies in patients in future studies. 
Overall, these results contribute to our mechanistic understanding of the action of, and 
resistance to corticosteroids, with potential broad applicability across a wide range of 
autoimmune and inflammatory diseases. These findings may also inform the development 
of a predictive biomarker of clinical corticosteroid refractory disease. In ITP, a CD4+ T cell-
based biomarker would benefit patients by enabling earlier initiation of alternative 
interventions in those unlikely to respond to corticosteroid. This would improve overall 
therapeutic success by minimizing the time during which patients have dangerously low 
platelet counts, reducing bleeding risk, and avoiding toxicity of ineffective corticosteroid 
treatment in refractory patients. 
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Age -- median (range) 53 (16-85) 50 (17-84) 38 (26-85) 61 (16-84) 
Female -- no. (%) 26 (46) 16 (48) 7 (58) 3 (27) 
ITP duration -- no. (%)     
        Newly diagnosed 21 (38) 16 (48) 3 (25) 2 (18) 
        Chronic 35 (63) 17 (52) 9 (75) 9 (82) 
Current treatment -- no. (%)     
        None 34 (61) 22 (67) 9 (75) 3 (27) 
        Corticosteroid 7 (13) 5 (15) 1 (8) 1 (9) 
        TPO RA  7 (13) 3 (9) 2 (17) 2 (18) 




Figure 1. Kinetics of IL-10, IL-17, and IFN-γ expression by CD4+ T cells in the presence of 
glucocorticoids. IL-10 (A, B) IL-17 (C) and IFN-γ (D) intracellular cytokine expression of CD4+ 
T cells from healthy controls were assessed by flow cytometry using a BD LSR II, and 
percentage of cells positive for each cytokine shown. Cells were activated in the presence 
(black circles) or absence (clear circles) of 1 x 10-6M dexamethasone (Dex) for the indicated 
number of days. The percentage of IL-10+ CD4+ T cells in response to a dose titration of Dex 
was compared at day 4 (B). Cumulative data shown, n=4. *p<0.05, ** p<0.01.  
Figure 2. CD4+ T cells from CR, PR and NR ITP patients exhibit distinct IL-10 and IL-17 
profiles in response to in vitro glucocorticoids. Intracellular cytokine expression of CD4+ T 
cells from ITP patients activated for 4 days in the presence or absence of 1 x 10-6M 
dexamethasone (Dex) were assessed by flow cytometry on a BD Fortessa X20. 
Representative flow cytometry plots for IL-10 and IL-17 (A) and cumulative data for the 
percentage of IL-10+ (B), IL-17+ (C) and IFN-γ+ (D) CD4+ T cells and the IL-10:IL-17 ratio (E) 
from ITP patients who clinically showed complete response (CR; n=33),  partial response 
(PR; n=12), or no response (NR; n=11) to corticosteroid treatment. Box plot of the IL-10:IL-
17 ratio of CD4+ T cells treated in vitro with dexamethasone from CR, PR and NR ITP patients 
(F).  Area under receiver operating characteristic (AUROC) curve for IL-10:IL-17 ratio in 
predicting the clinical response of ITP patients to corticosteroid treatment (G). AUROC is 
0.81 (95% confidence interval 0.668 to 0.952). (A-E) Mean +/- S.D. is shown. (F) Median, 
interquartile range, minimum and maximum values. *p<0.05, **p<0.01, ***p<0.001.  
Figure 3. CD4+ T cells from CR, PR and NR patients do not have distinct differences in 
cytokine levels directly ex vivo. IL-10 (A) IL-17 (B) and IFN-γ (C) intracellular cytokine 
expression, plus the calculated ratio of IL-10 to IL-17 expression (D) in CD4+ T cells isolated 
directly ex vivo from patient blood stimulated with PMA, ionomycin and GolgiStop for 4 
hours were assessed on a BD Fortessa X20. The percentage of all cells positive for each 
cytokine is shown. Patients were categorised by clinical response to corticosteroid 
treatment; complete response (CR; n=25), partial response (PR; n=10), or no response (NR; 
n=10). Mean +/- S.D. is shown.  
Figure 4. CD4+ T cells from corticosteroid non-responsive autoimmune uveitis patients 
demonstrate reduced IL-10:IL-17 ratio. Intracellular cytokine expression of CD4+ T cells from 
autoimmune uveitis patients activated for 4 days in the presence or absence of 1 x 10-6M 
dexamethasone (Dex) were assessed by flow cytometry on a BD LSR II. Representative flow 
cytometry plots for IL-10 and IL-17 (A) and cumulative data for the percentage of IL-10+ (B), 
IL-17+ (C) and IFNγ+ (D) CD4+ T cells and the IL-10:IL-17 ratio (E) from ITP patients who 
clinically showed complete response (CR; n=14) or no response (NR; n=22) to corticosteroid 
treatment. Box plot of the IL-10:IL-17 ratio of CD4+ T cells treated in vitro with 
dexamethasone from CR and NR uveitis patients (F).  Area under receiver operating 
characteristic (AUROC) curve for IL-10:IL-17 ratio in predicting the clinical response of ITP 
patients to corticosteroid treatment (G). AUROC is 0.76 (95% confidence interval 0.599 to 
0.914). (A-F) Mean +/- S.D. is shown. (F) Median, interquartile range, minimum and 
maximum values. *p<0.05, **p<0.01, ***p<0.001.  
